liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Combination therapy for preservation of beta cell function in Type 1 diabetes: New attitudes and strategies are needed!
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center of Paediatrics and Gynaecology and Obstetrics, Department of Paediatrics in Linköping.
2014 (English)In: Immunology Letters, ISSN 0165-2478, E-ISSN 1879-0542, Vol. 159, no 1-2, 30-35 p.Article, review/survey (Refereed) Published
Abstract [en]

In several diseases where the immune system plays an important role there has been a tremendous progress in treatment efficacy during the last decades. Based on necessary basic science these improvements are results of rapid, numerous and open-minded clinical trials where pieces of positive results step by step have been added into treatment schemes. Treatment of Type 1 diabetes has certainly improved but too slowly. It has been difficult to convince the scientific community of opinions which among non-professionals have been regarded as common sense such as the value of normal blood glucose and preservation of insulin secretion. Lack of motivation to participate in clinical trials has slowed down progress, as well as too narrow views on both pathogenesis of Type 1 diabetes and how studies should be designed to test therapeutic interventions. Studies in experimental animals can create and support hypothesis for human conditions but must not delay clinical trials too long. There is already evidence enough for intervention trials where immune suppression is combined with antigen treatment, beta cell protection, anti-inflammatory treatment, and efforts to stimulate beta cell regeneration. Regimens should be elaborated and first tried in those groups of patients where response can be expected to be best, and thereafter adjusted to increase efficacy step-wise, and in broader patient categories.

Place, publisher, year, edition, pages
Elsevier , 2014. Vol. 159, no 1-2, 30-35 p.
Keyword [en]
Type 1 diabetes; Immune intervention; C-peptide; Antigen treatment; Combination therapies; Beta cell regeneration
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-108810DOI: 10.1016/j.imlet.2014.02.006ISI: 000337018400005OAI: diva2:732891
Available from: 2014-07-07 Created: 2014-07-06 Last updated: 2014-07-07

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ludvigsson, Johnny
By organisation
Division of Clinical SciencesFaculty of Health SciencesDepartment of Paediatrics in Linköping
In the same journal
Immunology Letters
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 132 hits
ReferencesLink to record
Permanent link

Direct link